# Vivani Medical (VANI) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/VANI
## Company Profile
- Ticker: VANI
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
- Tags: Cardio-Metabolic
## Stock Data
- Close: 1.18 USD
- Market cap: 112105635.2 USD
- Last updated: 2026-10-13
## Business Overview
### Long-Acting Implant Company
Vivani Medical develops miniature drug implants intended to provide multi-month delivery of established medicines.
### NanoPortal Technology
The NanoPortal platform controls drug diffusion through a compact implant, with the goal of improving adherence and reducing treatment burden.
### NPM-139
NPM-139 is an ultra-long-acting semaglutide implant for chronic weight management and the lead program in Vivani’s SLIM clinical platform.
## Why The Stock Is Moving

As of Oct 13, 2026, VANI closed down 0.84% at $1.18. No new same-company headline was identified in the current news window.

## Future Catalysts

- Topline results from the Phase 1 SLIM-1 study of NPM-139 in November 2026.
- IND submission for NPM-139 to support a Phase 2 obesity study planned for 2027.
- Initiation of the Phase 2 NPM-139 dose-ranging study in 2027.

## Drug Assets

- SLIM-1

## Recent News
- 2026-10-12 11:00 EST — [Vivani Medical Announces Participation in Upcoming Investor Conferences](https://biopharmsignal.com/news/VANI/vivani-medical-announces-participation-in-upcoming-investor-conferences-9b2963ad) — Source: Vivani Medical
- 2026-08-13 20:05 EST — [Vivani Medical Reports Second Quarter 2026 Financial Results and Provides Business Update](https://biopharmsignal.com/news/VANI/vivani-medical-reports-second-quarter-2026-financial-results-and-provides-busine-aa8efb66) — Source: Vivani Medical
- 2026-08-06 12:00 EST — [Vivani Medical Announces Successful Dosing of All Participants in SLIM-1, a Phase 1 Trial Evaluating NPM-139, a Miniature, Ultra Long-Acting Semaglutide Implant for Chronic Weight Management](https://biopharmsignal.com/news/VANI/vivani-medical-announces-successful-dosing-of-all-participants-in-slim-1-a-phase-af1ac68e) — Source: Vivani Medical
- 2026-07-14 20:03 EST — [Vivani Medical to Present at the Emerging Growth Conference on July 15, 2026](https://biopharmsignal.com/news/VANI/vivani-medical-to-present-at-the-emerging-growth-conference-on-july-15-2026-793033b6) — Source: Vivani Medical
- 2026-07-07 11:35 EST — [Vivani Medical Enters into Agreement with Novo Nordisk to Evaluate NPM-139, a Miniature, Ultra Long-Acting Semaglutide Implant for Chronic Weight Management](https://biopharmsignal.com/news/VANI/vivani-medical-enters-into-agreement-with-novo-nordisk-to-evaluate-npm-139-a-min-9e9275ac) — Source: Vivani Medical